- Home
- AACG vs RLMD Comparison
AACG vs RLMD Comparison
Compare AACG & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- RLMD
- Stock Information
- Founded
- AACG 1999
- RLMD 2004
- Country
- AACG China
- RLMD United States
- Employees
- AACG N/A
- RLMD N/A
- Industry
- AACG Other Consumer Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- RLMD Health Care
- Exchange
- AACG Nasdaq
- RLMD Nasdaq
- Market Cap
- AACG 24.4M
- RLMD 22.0M
- IPO Year
- AACG N/A
- RLMD N/A
- Fundamental
- Price
- AACG $0.84
- RLMD $0.63
- Analyst Decision
- AACG
- RLMD Buy
- Analyst Count
- AACG 0
- RLMD 3
- Target Price
- AACG N/A
- RLMD $5.00
- AVG Volume (30 Days)
- AACG 11.8K
- RLMD 432.4K
- Earning Date
- AACG 08-06-2025
- RLMD 08-06-2025
- Dividend Yield
- AACG N/A
- RLMD N/A
- EPS Growth
- AACG N/A
- RLMD N/A
- EPS
- AACG N/A
- RLMD N/A
- Revenue
- AACG $37,997,003.00
- RLMD N/A
- Revenue This Year
- AACG N/A
- RLMD N/A
- Revenue Next Year
- AACG N/A
- RLMD N/A
- P/E Ratio
- AACG N/A
- RLMD N/A
- Revenue Growth
- AACG 21.24
- RLMD N/A
- 52 Week Low
- AACG $0.50
- RLMD $0.24
- 52 Week High
- AACG $1.10
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- AACG 51.28
- RLMD 51.09
- Support Level
- AACG $0.83
- RLMD $0.59
- Resistance Level
- AACG $0.80
- RLMD $0.67
- Average True Range (ATR)
- AACG 0.03
- RLMD 0.07
- MACD
- AACG 0.01
- RLMD -0.02
- Stochastic Oscillator
- AACG 81.18
- RLMD 52.97
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.